Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
25 March 2026
Read original ↗
🅇 This trial is currently recruiting participants in the UK
Speak to your GP or specialist first. They can help you understand if you might be eligible and what taking part would involve.
🅇 This trial is currently recruiting volunteers
If you think you might be eligible, speak to your GP or specialist about this trial before applying.
Status
Recruiting
Phase
N/A
Participants
ALL
Age Range
12 Years+
About This Trial
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
Who Can Join?
Inclusion Criteria: * Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®). * Adolescent and adult participants aged >=12 years with moderate-to-severe AD. * Participants who signed the written informed consent form (ICF) or had it signed by their legal representative. Exclusion Criteria: * Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label. * Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline. * Participants who received nemolizumab previously. * Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.
⚠ Always speak to your doctor before applying to any clinical trial.